NCT05798663
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05798663
Title Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alliance Foundation Trials, LLC.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego Moores Cancer Center La Jolla California 92037 United States Details
Kaiser Permanente Oakland Medical Center Oakland California 94611 United States Details
Kaiser Permanente Roseville Medical Center Roseville California 95661 United States Details
Kaiser Permanente San Francisco Medical Center San Francisco California 94115 United States Details
Kaiser Permanente Santa Clara Medical Center Santa Clara California 95051 United States Details
Kaiser Permanente Vallejo Medical Center Vallejo California 94589 United States Details
Rush University Medical Center Chicago Illinois 60612 United States Details
Washington University Siteman Cancer Center St Louis Missouri 63110 United States Details
Missouri Baptist Medical Center St Louis Missouri 63131 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
New Hampshire Oncology - Hematology, PA Manchester New Hampshire 03103 United States Details
Hematology Oncology Associates of Central New York, P.C. East Syracuse New York 13057 United States Details
SUNY Upstate Medical University Syracuse New York 13210 United States Details
Ohio State University Columbus Ohio 43210 United States Details
University of Wisconsin Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field